Ready-Made T Cells From Cord Blood Attacked Solid Tumors in Mice

Researchers have engineered immune cells from donated umbilical cord blood that recognise solid tumours through two separate detection systems and survive longer than earlier versions. In mice, the cells slowed tumour growth without the immune reaction that usually follows cells from an unmatched donor.

The problem being solved

Engineered T cell therapy has transformed the treatment of some blood cancers and has repeatedly disappointed in solid tumours. Two obstacles recur. The first is manufacturing: current approved products are made from each patient's own cells, which takes weeks and costs a great deal, and the sickest patients often cannot wait. The second is the tumour itself, which builds an environment that exhausts incoming immune cells and hides the markers they were built to find.

What is different here

The cells come from banked cord blood rather than from the patient, which makes them an off-the-shelf product -- available immediately and produced in batches. Cord blood immune cells are also less likely to attack the recipient's own tissue, which is what makes an unmatched donor viable at all.

The dual recognition system is aimed at the second problem. A tumour can evade a therapy that looks for a single marker simply by losing it -- a well-documented route to relapse. Requiring two signals raises the bar for escape, and it also narrows the risk of the cells attacking healthy tissue that happens to carry one of the two.

How far along it is

Mice. The animals showed slower tumour growth and the engineered cells persisted longer than comparable products, which is the specific weakness this design set out to address. Human trials have not been run, and the history of this field is that mouse tumour models are considerably more forgiving than human disease.

Bottom line

A thoughtful attempt at the two problems that have kept cell therapy out of solid tumours, at the stage where most such attempts still fail. Nothing here is available to patients, and no one should defer a recommended treatment in anticipation of it.